Clinical Trials Logo

Congenital Adrenal Hyperplasia clinical trials

View clinical trials related to Congenital Adrenal Hyperplasia.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT04457336 Terminated - Clinical trials for Congenital Adrenal Hyperplasia

A Ph2b to Evaluate Clinical Efficacy and Safety of Tildacerfont in Adult CAH

Start date: August 26, 2020
Phase: Phase 2
Study type: Interventional

An investigation of the efficacy and safety of up to 70 weeks of treatment with Tildacerfont in subjects with classic CAH who have elevated biomarkers at baseline on their current GC regimen. Optional open label treatment extension period up to 240 weeks with 200mg Tildacerfont QD.

NCT ID: NCT03669549 Terminated - Clinical trials for Congenital Adrenal Hyperplasia

Nevanimibe HCl for the Treatment of Classic CAH

Start date: July 11, 2018
Phase: Phase 2
Study type: Interventional

This is a multicenter, intra-subject dose-titration open-label study of nevanimibe hydrochloride (HCl) for the treatment of classic congenital adrenal hyperplasia (CAH). Following a Screening Period of approximately 2-14 weeks, eligible subjects will enter a Baseline Period of approximately 2-8 weeks and then a 16-week Treatment Period. It is anticipated that the overall duration of the study per subject will range from 24-42 weeks.